Martin David Harp

Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.

In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.

The study examines the effectiveness of PL9643 for the treatment of patients with dry eye disease.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

Jeff Todd talks about the campaign and partnering with actress Debbie Allen to help gain awareness on eye health.

The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.

AnnMarie Hipsley, DPT, PhD, sat down to speak about founding iAware, a non-for-profit organization established for the promotion of awareness of age-related ocular disease.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

The trial will be conducted by French tissue bank, TBF Génie Tissulaire.

The study from New Zealand was conducted on an otherwise healthy 28-year-old woman.

TOUR006 is an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED).

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

The company believes the 19-gauge filter needles may be the culprit in the SYFOVRE injections.

Canadian and Australian ophthalmologists and optometrists are looking ahead at the impact increased wildfire smoke can have on the ocular surface.

The trial is a prospective, multi-center, open label, single-armed trial which plans on enrolling 24 eligible subjects with cystoid macular edema.

The scholarships will be worth $1000 each and “aim to recognize innovation in myopia management and specialty contact lenses.”

This marks the 22nd time, and the 20th consecutive year, Bascom Palmer has received the No. 1 ranking by US News & World Report since the publication began surveying US physicians for its annual "Best Hospitals" rankings 34 years ago.

The trial will be an open-label trial in partnership with Tufts Medical Center. OK-101 is also being developed for use in dry eye disease.

The month will be dedicated to educating families on the importance of healthy vision and early access to healthcare.

The company also provided an update on tarcocimab development program for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

With lawsuits looming over the issue, the FDA has updated the label on Horizon Pharmaceutical’s drug for thyroid eye disease to include risks associated with hearing loss.

SriniVas R. Sadda, MD, discusses being president-elect of ARVO, as well as AI research being conducted at Doheny Eye Institute.

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

The Kansas-based company specializes in ophthalmic surgical equipment and services.

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.

The India-based pharmaceutical company is taking its first steps into ophthalmology with the announcement.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”